August 2018 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News

August 2018

What to Do When Your Grant Has Large Amounts of Unused Funding

Investigators with unobligated balances to carry forward should contact the NCI program officer (program director) for their grant. For more information, please see the NCI webpage with information about carryover requests.




New Webinar Series to Highlight Progress, Opportunities, and Challenges in Epidemiologic Studies of Rare Cancer

Rare Cancer Webinar Series Click to view the series.

The National Cancer Institute (NCI) defines a rare cancer as one that occurs in fewer than 15 out of 100,000 people per year; however, when taken together, rare cancers account for approximately 25% of all cancer cases that are diagnosed each year in the United States. Rare cancers are often associated with poorer outcomes, and large disparities in incidence and mortality rates for certain types have been documented, particularly in terms of race. Examples of rare cancers include: ovarian, pancreatic, esophageal, multiple myeloma, liver, and stomach.

Scientific program directors in NCI’s Epidemiology and Genomics Research Program (EGRP) have been assessing the landscape of population-based rare cancer research, as well as resources available to conduct rare cancer research, to identify knowledge gaps and needed resources for rare cancer research. This ongoing work has included the development of funding opportunity announcements (FOAs) that foster research on rare cancers. For example, PA-18-677 (R01) and PA-18-678 (R21) aim to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors and their interplay with established risk factors associated with the development of liver cancer in the United States.

There are numerous challenges to studying rare cancers, and, because of these challenges, there are large gaps in knowledge related to the prevention, diagnosis, and treatment of many types of rare cancers. Thus, EGRP has also developed a new webinar series focused on research on rare cancers. The purpose of this webinar series is twofold:

  1. To highlight work being done to investigate various aspects of rare cancers, including studies on etiology, risk, prognosis, and survivorship; and,
  2. To better understand the challenges, and strategies to overcome these challenges, related to studying rare cancers.

The first webinar in the Rare Cancer Webinar Series will take place on September 25, from 2:00 to 3:00 p.m. E.T. Brock Christensen, Ph.D., of Dartmouth’s Geisel School of Medicine will present on micro-RNA genetic variation related to head and neck cancer risk and survival. Learn more and/or register for this webinar.

For questions about EGRP’s Rare Cancer Webinar Series, contact Lisa Gallicchio, Ph.D., Program Director in EGRP’s Clinical and Translational Epidemiology Branch.

Funding Opportunities

  • Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01, R21 - Clinical Trial Optional)
  • Genomic Innovator Award (R35 - Clinical Trial Optional)
  • Modular R01s in Cancer Control and Population Sciences (R01 - Clinical Trial Optional)
  • Administrative Supplements to Support Cancer Disparity Collaborative Research (Admin Supp - Clinical Trial Optional)
  • Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 - Clinical Trial Required)

Grantsmanship Notices

  • NIH/AHRQ Application Submission/Resubmission Policy (NOT-OD-18-197)
  • Update on NIH's Next Generation Researchers Initiative (NGRI) Policy on Early Established Investigators (EEIs) (NOT-OD-18-214)

Return to Top